Literature DB >> 27230223

Describing Kawasaki shock syndrome: results from a retrospective study and literature review.

Andrea Taddio1,2, Eleonora Dei Rossi3, Lorenzo Monasta4, Serena Pastore4, Alberto Tommasini4, Loredana Lepore3, Gabriele Bronzetti5, Edoardo Marrani6, Biancamaria D'Agata Mottolese4, Gabriele Simonini6, Rolando Cimaz6, Alessandro Ventura3,4.   

Abstract

Kawasaki shock syndrome (KSS) is a rare manifestation of Kawasaki disease (KD) characterized by systolic hypotension or clinical signs of poor perfusion. The objectives of the study are to describe the main clinical presentation, echocardiographic, and laboratory findings, as well as the treatment options and clinical outcomes of KSS patients when compared with KD patients. This is a retrospective study. All children referred to two pediatric rheumatology units from January 1, 2012, to December 31, 2014, were enrolled. Patients were divided into patients with or without KSS. We compared the two groups according to the following variables: sex, age, type of KD (classic, with less frequent manifestations, or incomplete), clinical manifestations, cardiac involvement, laboratory findings, therapy administered, response to treatment, and outcome. Eighty-four patients with KD were enrolled. Of these, five (6 %) met the criteria for KSS. Patients with KSS had higher values of C-reactive protein (p = 0.005), lower hemoglobin levels (p = 0.003); more frequent hyponatremia (p = 0.004), hypoalbuminemia (p = 0.004), and coagulopathy (p = 0.003); and increase in cardiac troponins (p = 0.000). Among the KSS patients, three had a coronary artery involvement, but none developed a permanent aneurysm. Intravenous immunoglobulin resistance was more frequent in the KSS group, although not significantly so (3/5, 60 % vs. 23/79, 30 %, P = NS). None of the five cases was fatal, and all recovered without sequelae. KSS patients are more likely to have higher rates of cardiac involvement. However, most cardiovascular abnormalities resolved promptly with therapy.

Entities:  

Keywords:  Coronary artery involvement; Heart failure; Hypotension; Kawasaki disease; Kawasaki shock syndrome

Mesh:

Substances:

Year:  2016        PMID: 27230223     DOI: 10.1007/s10067-016-3316-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome.

Authors:  Pauline Gatterre; Mehdi Oualha; Laurent Dupic; Franck Iserin; Christine Bodemer; Fabrice Lesage; Philippe Hubert
Journal:  Intensive Care Med       Date:  2012-01-25       Impact factor: 17.440

2.  Analysis of the evidence for the lower limit of systolic and mean arterial pressure in children.

Authors:  Ikram U Haque; Arno L Zaritsky
Journal:  Pediatr Crit Care Med       Date:  2007-03       Impact factor: 3.624

3.  Shock: an unusual presentation of Kawasaki disease.

Authors:  Farah Thabet; Hend Bafaqih; Suleiman Al-Mohaimeed; Mariam Al-Hilali; Wafaa Al-Sewairi; May Chehab
Journal:  Eur J Pediatr       Date:  2011-02-24       Impact factor: 3.183

4.  Cardiogenic shock: do not forget the possibility of Kawasaki disease.

Authors:  Wei Wang; Wei-Hua Zhu; Yan-Qi Qi; Song-Ling Fu; Fang-Qi Gong
Journal:  Turk J Pediatr       Date:  2012 Jan-Feb       Impact factor: 0.552

5.  Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Authors:  Jane W Newburger; Lynn A Sleeper; Brian W McCrindle; L LuAnn Minich; Welton Gersony; Victoria L Vetter; Andrew M Atz; Jennifer S Li; Masato Takahashi; Annette L Baker; Steven D Colan; Paul D Mitchell; Gloria L Klein; Robert P Sundel
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

6.  Predicting IVIG resistance in UK Kawasaki disease.

Authors:  Sarah Davies; Natalina Sutton; Sarah Blackstock; Stuart Gormley; Clive J Hoggart; Michael Levin; Jethro A Herberg
Journal:  Arch Dis Child       Date:  2015-02-10       Impact factor: 3.791

7.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

8.  Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.

Authors:  Tohru Kobayashi; Tomio Kobayashi; Akihiro Morikawa; Kentaro Ikeda; Mitsuru Seki; Shinya Shimoyama; Yoichiro Ishii; Takahiro Suzuki; Kimiko Nakajima; Naoko Sakamoto; Hirokazu Arakawa
Journal:  J Pediatr       Date:  2013-02-26       Impact factor: 4.406

9.  Clinical manifestations associated with Kawasaki disease shock syndrome in Mexican children.

Authors:  Luisa Berenise Gámez-González; Chiharu Murata; Mireya Muñoz-Ramírez; Marco Yamazaki-Nakashimada
Journal:  Eur J Pediatr       Date:  2012-11-15       Impact factor: 3.183

10.  Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors:  Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal:  J Pediatr       Date:  2008-03-04       Impact factor: 4.406

View more
  20 in total

Review 1.  2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.

Authors:  Frank Zhu; Jocelyn Y Ang
Journal:  Curr Infect Dis Rep       Date:  2021-02-06       Impact factor: 3.725

2.  Myocardial fibrosis after adrenergic stimulation as a long-term sequela in a mouse model of Kawasaki disease vasculitis.

Authors:  Harry H Matundan; Jon Sin; Magali Noval Rivas; Michael C Fishbein; Thomas J Lehman; Shuang Chen; Roberta A Gottlieb; Timothy R Crother; Masanori Abe; Moshe Arditi
Journal:  JCI Insight       Date:  2019-02-07

3.  Kawasaki disease shock syndrome: A report of two cases and literature review.

Authors:  Qingyou Zhang; Ying Liao; Junbao Du
Journal:  Pediatr Investig       Date:  2019-06-25

4.  Adolescent Kawasaki disease shock syndrome with inflammatory cell infiltration into the myocardium: a case report.

Authors:  Yuki Sugiura; Takahiro Okumura; Toru Kondo; Toyoaki Murohara
Journal:  Eur Heart J Case Rep       Date:  2020-09-09

5.  Kawasaki Shock Syndrome in a 12-Year-Old Girl Mimicking Septic Shock.

Authors:  Vindika Prasad Sinhabahu; Janani Suntharesan; Dimuthu Saraji Wijesekara
Journal:  Case Rep Infect Dis       Date:  2016-12-22

6.  Unexplained Direct Hyperbilirubinemia and New-Onset Shock in a 17-Year-Old Male.

Authors:  Matthew Henry; Luke Horton; Jocelyn Y Ang
Journal:  Glob Pediatr Health       Date:  2020-05-29

7.  COVID-19 multisystem inflammatory syndrome in three teenagers with confirmed SARS-CoV-2 infection.

Authors:  Khuen Foong Ng; Trishul Kothari; Srini Bandi; Paul William Bird; Kanika Goyal; Mohammad Zoha; Vinayak Rai; Julian Wei-Tze Tang
Journal:  J Med Virol       Date:  2020-07-06       Impact factor: 2.327

Review 8.  Clinical features of acute kidney injury in patients with Kawasaki disease.

Authors:  Toru Watanabe
Journal:  World J Clin Pediatr       Date:  2018-08-30

9.  Incomplete Kawasaki disease complicated with acute abdomen: A case report.

Authors:  Tao Wang; Chuan Wang; Kai-Yu Zhou; Xiao-Qin Wang; Na Hu; Yi-Min Hua
Journal:  World J Clin Cases       Date:  2020-11-06       Impact factor: 1.337

10.  Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis.

Authors:  Hua Zou; Juan Lu; Jingjing Liu; Josiah Hiu-Yuen Wong; Si Cheng; Qiuhong Li; Yan Shen; Chunli Li; Xiaojiong Jia
Journal:  Int J Infect Dis       Date:  2020-11-14       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.